Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5179766
Max Phase: Preclinical
Molecular Formula: C19H17NO4S
Molecular Weight: 355.42
Associated Items:
ID: ALA5179766
Max Phase: Preclinical
Molecular Formula: C19H17NO4S
Molecular Weight: 355.42
Associated Items:
Canonical SMILES: COc1cc(/C=C2\SC(=O)NC2=O)ccc1OCc1ccc(C)cc1
Standard InChI: InChI=1S/C19H17NO4S/c1-12-3-5-13(6-4-12)11-24-15-8-7-14(9-16(15)23-2)10-17-18(21)20-19(22)25-17/h3-10H,11H2,1-2H3,(H,20,21,22)/b17-10-
Standard InChI Key: IPQOKWNEKIARGZ-YVLHZVERSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 355.42 | Molecular Weight (Monoisotopic): 355.0878 | AlogP: 3.91 | #Rotatable Bonds: 5 |
Polar Surface Area: 64.63 | Molecular Species: ACID | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 6.20 | CX Basic pKa: | CX LogP: 3.77 | CX LogD: 2.62 |
Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.82 | Np Likeness Score: -0.96 |
1. Madrigal-Angulo JL, Ménez-Guerrero C, Estrada-Soto S, Ramírez-Espinosa JJ, Almanza-Pérez JC, León-Rivera I, Hernández-Núñez E, Aguirre-Vidal Y, Flores-León CD, Aguayo-Ortíz R, Navarrete-Vazquez G.. (2022) Synthesis, in vitro, in silico and in vivo hypoglycemic and lipid-lowering effects of 4-benzyloxy-5-benzylidene-1,3-thiazolidine-2,4-diones mediated by dual PPAR α/γ modulation., 70 [PMID:35598791] [10.1016/j.bmcl.2022.128804] |
Source(1):